Partnership to Investigate Potential Drug Candidate

Contract Research Biotech (CRB) Inoviem Scientific has announced a service-based partnership with XoNovo, a preclinical-stage biopharmaceutical company developing a proprietary small molecule for the treatment of neurodegenerative diseases. Financial terms of the partnership were not disclosed.

The partnership aims to generate crucial information concerning XoNovo’s lead compound XN001, an autophagy modulator for the treatment of neurodegenerative diseases, involving application of solutions isolate and identify the compound’s therapeutic targets and elucidate its mode of action.
This partnership is in line with Inoviem’s long-term strategy, focused on broadening international connections, lowering risks in drug discovery and development projects, and supporting its partners in bringing promising therapeutics to the clinic with the ultimate goal of improving patients’ lives.

“There is uncertainty in all drug development processes. We must think anew. The goal of our collaboration with XoNovo is to provide a therapeutic solution for patients with neurodegenerative diseases,” said Dr. Pierre Eftekhari, founder and president of Inoviem Scientific.

“We are excited to collaborate with Inoviem and through this partnership, accelerate our technology with the aim of curing neurodegenerative diseases using the exciting novel mechanism of autophagy enhancement,” said Dr. Ido Nevo, XoNovo’s CEO.